We read with great interest the recent reports of recurrent mutations in the putative tumor suppressor gene ASXL1 that were published in this journal, as well as others. Several groups have reported the identification of missense, nonsense and frameshift mutations in ASXL1 in a wide spectrum of myeloid malignancies, including 11% of myelodysplastic syndrome, 17% acute myelogenous leukemia, 8% of myeloproliferative neoplasm, 43% of chronic myelomonocytic leukemia and 15% of chronic myelogenous leukemia patients. [1] [2] [3] [4] [5] In each of these publications, the most commonly reported mutation is an insertion of a guanine nucleotide at nucleotide position 1934 that results in a frameshift and resultant premature stop codon 12 codons downstream of the insertion (referred to as 'c.1934dupG; pGly646TrpfsX12'). Of note, this alteration accounted for 450% of the mutations found in ASXL1 in a series of myelodysplastic syndrome and acute myelogenous leukemia patient samples. 2 Close inspection of this variant in ASXL1, as displayed in a unidirectional trace without paired normal tissue in Figure 1 in the publication of Carbuccia et al., reveals that this variant occurs within an 8 base-pair mononucleotide guanine (G) nucleotide repeat (Figure 1a) . 4 Although the mononucleotide tract therein may represent a 'mutational hotspot', we became concerned that this frequently reported mutation might represent an artifact of PCR and/or sequencing, and not an actual somatic disease allele that contributes to myeloid transformation. It is noteworthy that the majority of reported mutations in ASXL1, including this allele, have not been assessed in paired normal DNA from the same individuals to ascertain if these mutations are acquired somatic mutations. [1] [2] [3] [4] [5] As part of our efforts to delineate the frequency of somatic an 8 base-pair guanine mononucleotide repeat sequence makes this reported variant suspicious for an artifact of PCR amplification rather than a true somatic mutation. This is a well-known phenomenon that is commonly seen as an artifact after PCR amplification of a region of DNA with homopolymer runs. 6, 7 Moreover, slipped-strand mispairing of the PCR polymerase resulting in this in vitro frameshift does not necessarily occur in every PCR amplification product, 6 ,7 which explains the variable presence of this allele in different patients as assessed by Sanger resequencing, which has limited sensitivity. To improve our ability to detect this variant, we perfomed amplification of this region of ASXL1 followed by sensitive mass spectrometry (Sequenom, San Diego, CA, USA) to distinguish between PCR products with 8 versus 9 guanine nucleotides in paired tumor and normal DNA (Figure 1b) . When we performed PCR amplification followed by (Seqeunom, San Diego, CA, USA) mass spectrometry for this variant in 10 paired samples from samples with myelodysplastic syndrome, myeloproliferative neoplasm and chronic myelomonocytic leukemia, this variant was detected in tumor and normal DNA in every instance. This again strongly suggests that this alteration is not a somatic mutation. Finally, we performed Sanger sequencing of ASXL1 in granulocyte DNA extracted from 96 individuals with no evidence of any hematologic disorder. The c.1934dupG p.Gly646TrpsfsX12 variant was readily apparent in 425% of samples from patients without hematologic disease (Figure 1c) . Although mutations in ASXL1 have been reported in individuals without clinical evidence of a hematologic disorder at the time of DNA acquisition, the fact that this sample is found repeatedly in paired tumor and normal DNA makes this unlikely to be a somatic mutation. 8 The findings reported above indicate that the most commonly reported mutation in ASXL1, to date, is not a somatic mutation. Much of the literature on the mutational frequency and clinical correlates of ASXL1 mutations should be reanalyzed with this in mind. The 8 mononucleotide guanine repeat sequence in the reference sequence for ASXL1 in this region may confound delimitation of the true repeat number in this region. These findings also further highlight the importance of the use of paired normal tissue for accurate detection of true somatic mutations rather than polymorphisms of PCR/sequencing artifacts.
Expression of cell-cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia Molecular characterization of leukemic cells is a continuously emerging field and has become fundamental for therapy stratification and prediction of event-free survival (EFS). Infant acute myeloid leukemia (AML) is in 460% cases characterized by a genomic rearrangement involving the mixed lineage leukemia (MLL) locus (11q23) and the expression of a fusion protein (450 fusion partners are described). Patients with primary diagnosis of MLL-positive leukemia are young (o2 years) and have generally an inferior outcome compared with MLL-negative patients. 1 We and others recently described a separate cohort of MLL-negative infant AML characterized by an early disease onset (o2 years) as well as t(7;12) HLXB9/TEL ( ¼ MNX1/ETV6) rearrangement and with concomitant high expression of HLXB9 (MNX1). Surprisingly, all patients relapsed having a 3-year EFS of 0%. 2, 3 The role of HLXB9, a transcription factor of the family of homeobox proteins is rarely studied in hematopoiesis and the data regarding its ability to cause malignant transformation of hematopoietic stem cells (HSCs) is not yet available. Interestingly, germline mutations of HLXB9 lead to annorectal malformations and Currarino syndrome in children, but hematopoietic abnormalities are not described. 4 The poor clinical outcome in this HLXB9/TEL-positive leukemia subset prompted us to comprehensively characterize the two
